Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894982 | 1.00 | HPGD (0.56) | HPGDALDH1A1KCNA5RAB9ACYP3A4 | |
| SCHEMBL490286 | 0.84 | ALDH1A1 (0.50) | HPGDALDH1A1KCNA5RAB9ACYP3A4 | |
| SCHEMBL2347309 | 0.84 | HPGD (0.57) | HPGDALDH1A1KCNA5KMT2ATSHR | |
| SCHEMBL5791483 | 0.84 | GRIA4 (0.49) | HPGDALDH1A1KCNA5RAB9AKMT2A | |
| SCHEMBL24155793 | 0.83 | HPGD (0.63) | HPGDALDH1A1RAB9ACYP3A4CYP2C19 | |
| SCHEMBL27562400 | 0.83 | KCNA5 (0.48) | HPGDALDH1A1KCNA5RAB9ACYP3A4 | |
| SCHEMBL2881396 | 0.83 | ESR1 (0.48) | HPGDALDH1A1RAB9AFFAR1CA12 | |
| SCHEMBL11442263 | 0.83 | TSHR (0.58) | HPGDALDH1A1RAB9ACYP3A4CYP2C19 | |
| SCHEMBL17754960 | 0.83 | RAB9A (0.51) | ALDH1A1RAB9AKMT2ANPSR1MEN1 | |
| SCHEMBL14567176 | 0.83 | ESR1 (0.48) | HPGDALDH1A1RAB9AFFAR1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2021-06-08 | — | — | US | disclosed |
| US-20200164024-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20120142748-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20110123555-A1 | PREPARATION AND UTILITY OF CCR5 INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| EP-0997534-B1 | Process for the resolution of racemic arylalkylcarboxylic acid esters | BASF AG (DE) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142748-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | CNR1, CNR2, GPR18 | HPGD 2022/4885ALDH1A1 4036/4885KCNA5 1156/4885 |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | HPGD 1460/4885ALDH1A1 4739/4885KCNA5 2567/4885 |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | HPGD 1460/4885ALDH1A1 4739/4885KCNA5 2567/4885 |
| US-20110123555-A1 | PREPARATION AND UTILITY OF CCR5 INHIBITORS | CCR5, CCR8, CCL5 | HPGD 1022/4885ALDH1A1 1332/4885KCNA5 4326/4885 |
| US-20200164024-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | HPGD 1460/4885ALDH1A1 4739/4885KCNA5 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.